Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
**Background:** Atrial fibrillation (AF) is a chronic sustained heart rhythm disorder associated with an increased risk of stroke. Apixaban, a new oral anticoagulant, was approved by the European Medicines Agency for prevention of stroke in patients with AF. The efficacy of apixaban has been investi...
Saved in:
Main Authors: | Yazid Aoudia, Thitima Kongnakorn, Evie Merinopoulou, Mohamed Said Bettayeb, Sid Ahmed Kherraf |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2017-05-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/9797 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Apixaban in Comparison to Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies
by: Muhammad U. Siddiqui, et al.
Published: (2019-01-01) -
Spontaneous Spinal Epidural Hematoma in a Patient on Apixaban for Nonvalvular Atrial Fibrillation
by: Ahmad El Alayli, et al.
Published: (2020-01-01) -
The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria
by: Nadir Hammoumraoui, et al.
Published: (2013-10-01) -
Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
by: Carlos Rubio-Terrés, et al.
Published: (2016-02-01) -
Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation and Hereditary Hemorrhagic Telangiectasia
by: Sebastiaan Velthuis, et al.
Published: (2012-01-01)